2026 Subacute cutaneous lupus erythematosus indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and…

2026 Folliculitis decalvans indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Erosive pustular dermatosis of the scalp indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and…

2026 Perifolliculitis capitis abscedens et suffodiens indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need,…

2026 Acne fulminans indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Hidradenitis suppurativa Hurley stage III indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and…

2026 Papillon-Lefevre syndrome indication strategy covering epidemiology, CTSC biology, active trials, transactions, unmet need, competition and market…

2026 Pachyonychia congenita indication strategy covering epidemiology, KRT6A biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Olmsted syndrome indication strategy covering epidemiology, TRPV3 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Palmoplantar keratoderma indication strategy covering epidemiology, KRT9 biology, active trials, transactions, unmet need, competition and market…

2026 Keratoderma blennorrhagicum indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and market…

2026 Epidermolytic ichthyosis indication strategy covering epidemiology, KRT10 biology, active trials, transactions, unmet need, competition and market…